Row:	2018 	2017 	2016
Row:Sales 	$ 42,294 $ 	40,122 	$ 39,807
Row:Costs, Expenses and Other
			Row:Cost of sales 	13,509 	12,912 	14,030
Row:Selling, general and administrative 	10,102 	10,074 	10,017
Row:Research and development 	9,752 	10,339 	10,261
Row:Restructuring costs 	632 	776 	651
Row:Other (income) expense, net 	(402) 	(500) 	189
Row:	33,593 	33,601 	35,148
Row:Income Before Taxes 	8,701 	6,521 	4,659
Row:Taxes on Income 	2,508 	4,103 	718
Row:Net Income 	6,193 	2,418 	3,941
Row:Less: Net (Loss) Income Attributable to Noncontrolling Interests 	(27) 	24 	21
Row:Net Income Attributable to Merck & Co., Inc. 	$ 6,220 $ 	2,394 	$ 3,920
Row:Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common
Shareholders 	$ 2.34 $ 	0.88 	$ 1.42
Row:Earnings per Common Share Assuming Dilution Attributable to Merck & Co.,
Inc. Common Shareholders 	$ 2.32 $ 	0.87 	$ 1.41
Row:Net Income Attributable to Merck & Co., Inc. $ 	6,220 	$ 2,394 	$ 3,920
Row:Other Comprehensive (Loss) Income Net of Taxes:
			Row:Net unrealized gain (loss) on derivatives, net of reclassifications 	297 	(446) 	(66)
Row:Net unrealized loss on investments, net of reclassifications 	(10) 	(58) 	(44)
Row:Benefit plan net (loss) gain and prior service (cost) credit, net of amortization 	(425) 	419 	(799)
Row:Cumulative translation adjustment 	(223) 	401 	(169)
Row:	(361) 	316 	(1,078)
Row:Comprehensive Income Attributable to Merck & Co., Inc. $ 	5,859 	$ 2,710 	$ 2,842
Row:Assets
		Row:Current Assets
		Row:Cash and cash equivalents $ 	7,965 $ 	6,092
Row:Short-term investments 	899 	2,406
Row:Accounts and $159 receivable in 2017) (net of allowance for doubtful accounts of $119 in 2018
	7,071 	6,873
Row:Inventories classified (excludes in Other assets inventories - see Note of $1,417 7) in 2018 and $1,187 in 2017
	5,440 	5,096
Row:Other current assets Total current assets 	4,500 25,875 	4,299
24,766
Row:Investments 	6,233 	12,125
Row:Property, Plant and Equipment (at cost)
		Row:Land 	333 	365
Row:Buildings 	11,486 	11,726
Row:Machinery, equipment and office furnishings 	14,441 	14,649
Row:Construction in progress 	3,355 	2,301
Row:	29,615 	29,041
Row:Less: accumulated depreciation 	16,324 	16,602
Row:	13,291 	12,439
Row:Goodwill 	18,253 	18,284
Row:Other Intangibles, Net 	11,431 	14,183
Row:Other Assets 	7,554 	6,075
Row:$ 	82,637 $ 	87,872
Row:Liabilities and Equity
		Row:Current Liabilities
		Row:Loans payable and current portion of long-term debt $ 	5,308 $ 	3,057
Row:Trade accounts payable 	3,318 	3,102
Row:Accrued and other current liabilities 	10,151 	10,427
Row:Income taxes payable 	1,971 	708
Row:Dividends payable 	1,458 	1,320
Row:Total current liabilities 	22,206 	18,614
Row:Long-Term Debt 	19,806 	21,353
Row:Deferred Income Taxes 	1,702 	2,219
Row:Common Authorized stock, - 6,500,000,000 $0.50 par value
shares
Issued - 3,577,103,522 shares in 2018 and 2017
	1,788 1,788
Row:Other paid-in capital 	38,808 39,902
Row:Retained earnings 	42,579 41,350
Row:Accumulated other comprehensive loss 	(5,545) (4,910)
Row:Less 984,543,979 treasury stock, shares at in cost:
2018 and 880,491,914 shares in 2017 	77,630 78,130
50,929 43,794
Row:Total Merck & Co., Inc. stockholders’ equity 	26,701 34,336
Row:Noncontrolling Interests 	181 233
Row:Total equity 	26,882 34,569
Row:	$ 82,637 $ 87,872
Row:2018 	2017 	2016
Row:Cash Flows from Operating Activities
		Row:Net income $ Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization Intangible asset impairment charges 	6,193 $ 2,418 4,519 4,676 296 646 	$ 3,941
5,471
3,948
Row:Charge for future payments related to collaboration license options 	650 500 	—
Row:Provisional charge for one-time transition tax related to the enactment of U.S. tax
legislation 	— 5,347 	—
Row:Charge related to the settlement of worldwide Keytruda patent litigation 	— — 	625
Row:Deferred income taxes 	(509) (2,621) 	(1,521)
Row:Share-based compensation 	348 312 	300
Row:Other Net changes in assets and liabilities:
	978 190 	213
Row:Accounts receivable 	(418) 297 	(619)
Row:Inventories 	(911) (145) 	206
Row:Trade accounts payable 	230 254 	278
Row:Accrued and other current liabilities 	(341) (922) 	(2,018)
Row:Income taxes payable 	827 (3,291) 	124
Row:Noncurrent liabilities 	(266) (123) 	(809)
Row:Other 	(674) (1,087) 	237
Row:Net Cash Provided by Operating Activities 	10,922 6,451 	10,376
Row:Cash Flows from Investing Activities
		Row:Capital expenditures Purchases of securities and other investments 	(2,615) (1,888) (7,994) (10,739) 	(1,614)
(15,651)
Row:Proceeds from sales of securities and other investments Acquisitions, net of cash acquired Other 	15,252 15,664 (431) (396) 102 38 	14,353
(780)
482
Row:Net Cash Provided by (Used in) Investing Activities 	4,314 2,679 	(3,210)
Row:Cash Flows from Financing Activities
Net change in short-term borrowings 	5,124 (26) 	—
Row:Payments on debt 	(4,287) (1,103) 	(2,386)
Row:Proceeds from issuance of debt 	— — 	1,079
Row:Purchases of treasury stock 	(9,091) (4,014) 	(3,434)
Row:Dividends paid to stockholders 	(5,172) (5,167) 	(5,124)
Row:Proceeds from exercise of stock options Other 	591 499 (325) (195) 	939
(118)
Row:Net Cash Used in Financing Activities 	(13,160) (10,006) 	(9,044)
Row:Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $4 million of
restricted cash at January 1, 2018 included in Other Assets) 	(205) 457 1,871 (419) 6,096 6,515 	(131)
(2,009)
8,524
Row:Cash, Cash Equivalents and Restricted Cash at End of Year (includes $2 million of
restricted cash at December 31, 2018 included in Other Assets) $ 	7,967 $ 6,096 	$ 6,515
